"instanceType","name","description","label","uuid:ID","rationale","id"
"StudyDesign","Study Design 1","The main design for the study","","70b82e1d-e38a-4233-a618-222b484f592a","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
